Literature DB >> 17632007

A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice.

Veronica F Colomer Gould1, Daniel Goti, Donna Pearce, Guillermo A Gonzalez, Hong Gao, Mario Bermudez de Leon, Nancy A Jenkins, Neal G Copeland, Christopher A Ross, Dale R Brown.   

Abstract

Machado-Joseph disease also called spinocerebellar ataxia type 3 (MJD/SCA3) is a hereditary and neurodegenerative movement disorder caused by ataxin-3 with a polyglutamine expansion (mutant ataxin-3). Neuronal loss in MJD/SCA3 is associated with a mutant ataxin-3 toxic fragment. Defining mutant ataxin-3 proteolytic site(s) could facilitate the identification of the corresponding enzyme(s). Previously, we reported a mutant ataxin-3 mjd1a fragment in the brain of transgenic mice (Q71) that contained epitopes C-terminal to amino acid 220. In this study, we generated and characterized neuroblastoma cells and transgenic mice expressing mutant ataxin-3 mjd1a lacking amino acids 190-220 (deltaQ71). Less deltaQ71 than Q71 fragments were detected in the cell but not mouse model. The transgenic mice developed an MJD/SCA3-like phenotype and their brain homogenates had a fragment containing epitopes C-terminal to amino acid 220. Our results support the toxic fragment hypothesis and narrow the mutant ataxin-3 cleavage site to the N-terminus of amino acid 190.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17632007      PMCID: PMC2040168          DOI: 10.1016/j.nbd.2007.06.005

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  57 in total

1.  Isolation of neuronal cells with high processing activity for the Machado-Joseph disease protein.

Authors:  Y Yamamoto; H Hasegawa; K Tanaka; A Kakizuka
Journal:  Cell Death Differ       Date:  2001-08       Impact factor: 15.828

2.  Polyglutamine repeat length-dependent proteolysis of huntingtin.

Authors:  Banghua Sun; Wei Fan; Aldona Balciunas; Jillian K Cooper; Gal Bitan; Shirley Steavenson; Paul E Denis; Yunjen Young; Beverly Adler; Larry Daugherty; Raffi Manoukian; Gary Elliott; Wenyan Shen; Jane Talvenheimo; David B Teplow; Mitsuru Haniu; Raj Haldankar; Jette Wypych; Christopher A Ross; Martin Citron; William G Richards
Journal:  Neurobiol Dis       Date:  2002-10       Impact factor: 5.996

3.  Intermediate CAG repeat lengths (53,54) for MJD/SCA3 are associated with an abnormal phenotype.

Authors:  N van Alfen; R J Sinke; M J Zwarts; A Gabreëls-Festen; P Praamstra; B P Kremer; M W Horstink
Journal:  Ann Neurol       Date:  2001-06       Impact factor: 10.422

4.  A survey of spinocerebellar ataxia in South Brazil - 66 new cases with Machado-Joseph disease, SCA7, SCA8, or unidentified disease-causing mutations.

Authors:  L B Jardim; I Silveira; M L Pereira; A Ferro; I Alonso; M do Céu Moreira; P Mendonça; F Ferreirinha; J Sequeiros; R Giugliani
Journal:  J Neurol       Date:  2001-10       Impact factor: 4.849

5.  Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity.

Authors:  J Hara; C T Beuckmann; T Nambu; J T Willie; R M Chemelli; C M Sinton; F Sugiyama; K Yagami; K Goto; M Yanagisawa; T Sakurai
Journal:  Neuron       Date:  2001-05       Impact factor: 17.173

6.  Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities.

Authors:  Fusheng Li; Todd Macfarlan; Randall N Pittman; Debabrata Chakravarti
Journal:  J Biol Chem       Date:  2002-09-23       Impact factor: 5.157

7.  Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis.

Authors:  Y J Kim; Y Yi; E Sapp; Y Wang; B Cuiffo; K B Kegel; Z H Qin; N Aronin; M DiFiglia
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

8.  Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.

Authors:  Cheryl L Wellington; Lisa M Ellerby; Claire-Anne Gutekunst; Danny Rogers; Simon Warby; Rona K Graham; Odell Loubser; Jeremy van Raamsdonk; Roshni Singaraja; Yu-Zhou Yang; Juliette Gafni; Dale Bredesen; Steven M Hersch; Blair R Leavitt; Sophie Roy; Donald W Nicholson; Michael R Hayden
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

9.  Calpain activation in Huntington's disease.

Authors:  Juliette Gafni; Lisa M Ellerby
Journal:  J Neurosci       Date:  2002-06-15       Impact factor: 6.167

10.  Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions.

Authors:  Astrid Lunkes; Katrin S Lindenberg; Léa Ben-Haïem; Chantal Weber; Didier Devys; G Bernhard Landwehrmeyer; Jean-Louis Mandel; Yvon Trottier
Journal:  Mol Cell       Date:  2002-08       Impact factor: 17.970

View more
  22 in total

Review 1.  Toward understanding Machado-Joseph disease.

Authors:  Maria do Carmo Costa; Henry L Paulson
Journal:  Prog Neurobiol       Date:  2011-11-23       Impact factor: 11.685

Review 2.  Genetically engineered mouse models of the trinucleotide-repeat spinocerebellar ataxias.

Authors:  Melissa A C Ingram; Harry T Orr; H Brent Clark
Journal:  Brain Res Bull       Date:  2011-07-23       Impact factor: 4.077

Review 3.  Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease.

Authors:  Dagmar E Ehrnhoefer; Liza Sutton; Michael R Hayden
Journal:  Neuroscientist       Date:  2011-02-10       Impact factor: 7.519

Review 4.  PolyQ disease: misfiring of a developmental cell death program?

Authors:  Elyse S Blum; Andrew R Schwendeman; Shai Shaham
Journal:  Trends Cell Biol       Date:  2012-12-08       Impact factor: 20.808

Review 5.  Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives.

Authors:  J J Magaña; L Velázquez-Pérez; B Cisneros
Journal:  Mol Neurobiol       Date:  2012-09-21       Impact factor: 5.590

Review 6.  Mouse models of spinocerebellar ataxia type 3 (Machado-Joseph disease).

Authors:  Veronica F Colomer Gould
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

7.  Antisense oligonucleotide therapy rescues aggresome formation in a novel spinocerebellar ataxia type 3 human embryonic stem cell line.

Authors:  Lauren R Moore; Laura Keller; David D Bushart; Rodrigo G Delatorre; Duojia Li; Hayley S McLoughlin; Maria do Carmo Costa; Vikram G Shakkottai; Gary D Smith; Henry L Paulson
Journal:  Stem Cell Res       Date:  2019-07-16       Impact factor: 2.020

8.  Understanding the role of the Josephin domain in the PolyUb binding and cleavage properties of ataxin-3.

Authors:  Giuseppe Nicastro; Sokol V Todi; Ezgi Karaca; Alexandre M J J Bonvin; Henry L Paulson; Annalisa Pastore
Journal:  PLoS One       Date:  2010-08-26       Impact factor: 3.240

9.  Polyglutamine-expanded androgen receptor truncation fragments activate a Bax-dependent apoptotic cascade mediated by DP5/Hrk.

Authors:  Jessica E Young; Gwenn A Garden; Refugio A Martinez; Fumiaki Tanaka; C Miguel Sandoval; Annette C Smith; Bryce L Sopher; Amy Lin; Kenneth H Fischbeck; Lisa M Ellerby; Richard S Morrison; J Paul Taylor; Albert R La Spada
Journal:  J Neurosci       Date:  2009-02-18       Impact factor: 6.167

10.  Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3.

Authors:  Joonil Jung; Kexiang Xu; Derek Lessing; Nancy M Bonini
Journal:  Hum Mol Genet       Date:  2009-09-25       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.